Reading LGVN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LGVN free→Reading LGVN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LGVN free→QuarterlyIQ Insights · LGVN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Chief Financial Officer — Lisa Locklear: Ms. Lisa Locklear is stepping down as CFO, and her successor has not been finalized.
Results of Operations and Financial Condition On May 13, 2026, Longeveron Inc. (the “Company”) issued a press release announcing its financial and operating results for the three months ended March 31, 2026 and certain other business updates and information. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for…
Other Events. On May 8, 2026, Longeveron Inc. (the Company) issued a press release announcing that a constructive Type C meeting with the U.S. Food and Drug Administration (FDA or Agency) was held in late March, with the FDA providing their meeting summary in late April, to discuss the ongoing development of laromestrocel (LOMECEL-B®), a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase 2b clinical trial (ELPIS II) for hypoplastic left he…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) As previously disclosed, in connection with the ongoing review of its cash runway and cost structure, and following Board approval, Longeveron Inc. (the “Company”) implemented a temporary reduction in the compensation or fees payable, as applicable, of its executive officers and Board of Directors (the “Board”), effective on or about February 1…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously announced, on September 22, 2025, Longeveron Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) advising that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement…
Other Events. On March 23, 2026, Longeveron Inc. (the “Company”) cancelled its special meeting of stockholders scheduled to be held in 2026 (the “Special Meeting”). The Company currently intends for the “Reverse Stock Split” proposal set forth in the preliminary proxy statement relating to the Special Meeting, which was filed with the U.S. Securities and Exchange Commission on March 3, 2026, to instead be presented at the Company’s next regularly scheduled annual meeting of stockholders to th…
Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 10, 2026, Longeveron Inc., a Delaware corporation (the “Company”), entered into a Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (each, an “Investor” and collectively, the “Investors”), pursuant to which the Company agreed to issue and sell shares of the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”) and, shares of the Company’s…
Other Events. On March 10, 2026, the Company issued a press release announcing the pricing of the Private Placement. On March 11, 2026, the Company issued a press release announcing the Initial Closing of the Private Placement. Copies of the press releases are attached as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference. 5 Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K and certain of the materials filed herewith contain forwa…
Unregistered Sales of Equity Securities The matters described in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 3, 2026, Mr. Richard Kender provided notice of his resignation from the Company’s Board of Directors (the “Board”) and Audit Committee, to be effective immediately. Mr. Kender indicated that his decision to resign was due to his changing role at Seres Therapeutics, where he has served on the Board for nearly 12 years, as Seres had just ann…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On March 4, 2026 Longeveron Inc. (the “Company”) notified Nasdaq that, as a result of the resignation of Mr. Richard Kender as a member of the Board of Directors (the “Board”) of the Company and as chairman of the Audit Committee and the audit committee financial expert, as described below, the Company temporarily was no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which require…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 9, 2026, Than Powell, Interim Chief Executive Officer of Longeveron Inc. (the “Company”), provided notice to the Company of his resignation as Interim Chief Executive Officer of the Company, but will remain with the Company in his prior business development role. In connection with Mr. Powell’s departure, the Board has appointed Stephen…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On November 7, 2025, Mr. Khoso Baluch and Ms. Neha Motwani provided notices of each of their resignations from the Board of Directors (the “Board”) of Longeveron Inc. (the “Company”) to be effective immediately. Neither Mr. Baluch nor Ms. Motwani indicated that their respective decisions to resign was due to any disagreement with the Company on…
Results of Operations and Financial Condition On November 4, 2025, Longeveron Inc. (the “Company”) issued a press release announcing its financial and operating results for the three and nine months ended September 30, 2025 and certain other business updates and information. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information provided under this Form 8-K (including Exhibit 99.1) shall not be de…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 25, 2025, the Board of Directors (the “Board”) of Longeveron Inc. (the “Company”) approved Dr. George Paletta, age 63, to fill a current vacancy on the Board as a Class I director, effective October 1, 2025. In connection with his appointment to the Board, Dr. Paletta will receive compensation consistent with the Board’s current compen…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 22, 2025, Longeveron Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that the Company’s Class A common stock (“Common Stock”) did not meet the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price…
Entry into a Material Definitive Agreement. On September 19, 2025, Longeveron Inc., a Delaware corporation (the “Company”), entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) providing for the sale and issuance by the Company of shares of its Class A common stock, par value $0.001 per share (the “Common Stock”) from time to time, through or to Wainwright as the Company’s sales agent or principal in an “at the market offering”…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2025, Longeveron Inc. (the “Company”) and Wa’el Hashad, Chief Executive Officer, determined that Mr. Hashad would step down from his role as Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), effective immediately, so as to allow Mr. Hashad to pursue other opportunities. In connection with Mr. Hashad…
Results of Operations and Financial Condition On August 13, 2025, Longeveron Inc. (the “Company”) issued a press release announcing its financial and operating results for the three and six months ended June 30, 2025 and certain other business updates and information. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “f…
Other Events. On August 8, 2025, the Company issued a press release announcing the pricing of the Offering. On August 11, 2025, the Company issued a press release announcing the closing of the Offering. Copies of the press releases are attached as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K and certain of the materials filed herewith contain forward-looking statements withi…
Entry into a Material Definitive Agreement. On August 8, 2025, Longeveron Inc. (the “Company”) commenced a public offering (the “Offering”) of (i) 5,617,648 shares (the “Shares”) of the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”) and (ii) pre-funded warrants to purchase up to an aggregate of 264,706 shares of Common Stock (the “Pre-Funded Warrants”). The Shares and Pre-Funded Warrants were sold together with Class A common warrants (the “Common Warrants”) t…
Results of Operations and Financial Condition On May 8, 2025, Longeveron Inc. (the “Company”) issued a press release announcing its financial and operating results for the three months ended March 31, 2025 and certain other business updates and information. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On April 24, 2025, the Compensation Committee of the Board of Directors of Longeveron Inc. (the “Company”) confirmed continued approval of the Company’s Cash-to-Equity Program on an ongoing basis, as adjusted to include the application of a Black-Scholes multiplier. Initially authorized in May 2024 on an emergency basis, the original program pr…
Changes in Registrant’s Certifying Accountant. (a) Resignation of Independent Registered Public Accounting Firm On March 13, 2025, Longeveron Inc. (the “Company”) was notified by Marcum LLP (“Marcum”) that Marcum resigned as the Company’s independent registered public accounting firm. On November 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum. Substantially all of the partners and staff that provided attestation services with Marcum joined CBIZ. On March 13, 2025, Mar…
Results of Operations and Financial Condition On February 28, 2025, Longeveron Inc. (the “Company”) issued a press release announcing its results for the fourth fiscal quarter ended December 31, 2024 and certain other business updates and information. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for any pur…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.